Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tamjeed Arshad

Clinical Cardiac Electrophysiology Montgomery, AL Medical Doctor

NPI 1568492544 CMS profile 343569

2055 East South Blvd, Suite 403, Montgomery, AL 36116

Open in the dashboard

General payments

$36,661

442 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$858 paid to institutions, not to them · program year 2019

Through program year 2025, Tamjeed Arshad of Montgomery, AL is reported in the CMS Open Payments database as having received $36,661 across 442 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $858 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,260 54
2024 General $2,690 57
2023 General $3,753 67
2022 General $6,612 65
2021 General $8,234 65
2020 General $6,010 40
2019 General $8,102 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamjeed Arshad
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Tamjeed Arshad were reported at $1,260. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Tamjeed Arshad Clinical Cardiac Electrophysiology median Middle half National median
2019 $8,102 $2,361 $585–$8,260 $163
2020 $6,010 $993 $247–$4,351 $114
2021 $8,234 $1,185 $326–$4,739 $132
2022 $6,612 $2,073 $554–$6,789 $149
2023 $3,753 $2,568 $759–$8,159 $160
2024 $2,690 $2,557 $703–$7,403 $164
2025 $1,260 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25,472 69 payments
  2. Abbott Laboratories $2,953 28 payments
  3. Medtronic, Inc. $1,148 19 payments
  4. Pfizer Inc. $999 65 payments
  5. Medtronic Vascular, Inc. $679 14 payments
  6. Novartis Pharmaceuticals Corporation $635 46 payments
  7. Janssen Pharmaceuticals, Inc $559 24 payments
  8. Edwards Lifesciences Corporation $476 5 payments
  9. E.R. Squibb & Sons, L.L.C. $473 27 payments
  10. Amgen Inc. $396 25 payments
  11. Other $2,872 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,000 21 payments
  2. Food and Beverage $9,932 405 payments
  3. Consulting Fee $1,950 8 payments
  4. Education $438 5 payments
  5. Travel and Lodging $341 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $25,472 69 payments
  2. Fortify Assura, Ellipse ICD $1,482 6 payments
  3. XARELTO $670 25 payments
  4. Micra $637 8 payments
  5. ELIQUIS $610 43 payments
  6. VYNDAQEL $575 37 payments
  7. Arctic Front $526 9 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $476 5 payments
  9. VERQUVO $469 28 payments
  10. Accent Pacemaker $468 2 payments
  11. Other $6,640 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

3,211

Median for Cardiology: 2,533

Drug cost

$2,286,027

Median for Cardiology: $485,213

Branded share of claims

38.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 52 $1,332,248
Eliquis Apixaban Brand 385 $355,892
Entresto Sacubitril/Valsartan Brand 175 $185,818
Farxiga Dapagliflozin Propanediol Brand 117 $108,430
Jardiance Empagliflozin Brand 77 $84,121
Xarelto Rivaroxaban Brand 65 $70,970
Multaq Dronedarone Hcl Brand 50 $58,989
Repatha Sureclick Evolocumab Brand 37 $27,090
Brilinta Ticagrelor Brand 20 $16,182
Vascepa Icosapent Ethyl Brand 12 $12,082

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$88,475

Medicare's payments for the services billed

Medicare patients

430

Average age 76

Services billed

1,711

200 women, 230 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 53%
Atrial fibrillation 50%
Chronic kidney disease 46%
Diabetes 43%
Heart failure 37%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $181
$181 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $51
  • PFIZER INC. $35
$85 385 —
VYNDAQEL
  • PFIZER INC. $85
$85 — —
Repatha
  • Amgen Inc. $64
$64 37 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
$46 77 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

442 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record